WHAT’S BEING CLAIMED:
- The selling of Kratom, a supplement that contains addictive substances, is now being halted by the FDA.
- Warnings have been issued by the U.S. Food and Drug Administration to two companies who are still selling the controversial supplement.
- Both companies have advertised illegal claims about the use of Kratom for opioid addiction.
Chillin Mix Kratom and Mitra Distributing have been identified as the two companies that continue selling kratom supplements on their websites despite the FDA’s attempt to suppress the regulation of the substance. Two pounds of kratom powder is available for only $65 at Chillin Mix and Mitra offers the supplement wholesale.
FDA’s warning letters to both companies on September 4 were made public on Tuesday, stating that both businesses advertise illegally. They reportedly have been promoting kratom supplements as a treatment for opioid addiction, withdrawal symptoms, even depression, alcoholism and high blood pressure.
Earlier this year, the FDA stated that kratom contains opioid-like properties and should not be used for any medical treatment, as there is no proof that the supplement is harmless and therapeutic. They further stated that 44 deaths have been linked with the controversial product.
On Tuesday, the FDA released a statement saying, “Simply, selling these unapproved kratom products with claims that they can treat opioid withdrawal and addiction and other serious medical conditions is a violation of federal law.”
“Yet despite our warnings and previous regulatory and enforcement actions, we continue to find marketers actively selling kratom with unsubstantiated claims.”
The Centers for Disease Control and Prevention said that there have been over 600,000 deaths in the US in relation to opioid overdoses from 1999 to 2016.
But even now, there are many factors that make it difficult to get opioid treatments, according to public health experts. U.S agencies are currently working on developing better pain medication and FDA-approved substances to treat opioid addiction.
Source: Market Watch